摘要
Purpose: Several cytokines involved in the development of sickness behaviors are considered to be related to the development of cancer symptoms. However, the mechanism of cytokines' involvement in symptom relief with gefitinib treatment remains unknown. This study analyzed the relationships between single symptoms/symptom clusters and cytokines in patients with advanced non-small-cell lung cancer (NSCLC) at pretreatment and at 1 month, 3 months, and 6 months after gefitinib treatment. Methods: Fifty-seven patients with NSCLC were recruited via convenience sampling from a group of thoracic oncology patients in Northern Taiwan. Research measures included the use of the M.D. Anderson Symptom Inventory-Taiwan form and enzyme-linked immunosorbent assays. Statistical analyses included descriptive statistics and generalized estimating equation analysis. Results: Positive relationships were observed between interleukin (IL)-2 and nausea (p
| 原文 | 英語 |
|---|---|
| 頁（從 - 到） | 50-56 |
| 頁數 | 7 |
| 期刊 | Journal of Experimental and Clinical Medicine(Taiwan) |
| 卷 | 6 |
| 發行號 | 2 |
| DOIs | |
| 出版狀態 | 已發佈 - 2014 |
指紋
ASJC Scopus subject areas
- Medicine(all)
引用此文
Relationship of cytokines to symptom distress and symptom clusters among non-small-cell lung cancer patients receiving gefitinib treatment : A pilot study. / Wang, Shu Yi; Tsai, Chun Ming; Lin, Chia-Chin.
於: Journal of Experimental and Clinical Medicine(Taiwan), 卷 6, 編號 2, 2014, p. 50-56.研究成果: 雜誌貢獻 › 文章
}
TY - JOUR
T1 - Relationship of cytokines to symptom distress and symptom clusters among non-small-cell lung cancer patients receiving gefitinib treatment
T2 - A pilot study
AU - Wang, Shu Yi
AU - Tsai, Chun Ming
AU - Lin, Chia-Chin
PY - 2014
Y1 - 2014
N2 - Purpose: Several cytokines involved in the development of sickness behaviors are considered to be related to the development of cancer symptoms. However, the mechanism of cytokines' involvement in symptom relief with gefitinib treatment remains unknown. This study analyzed the relationships between single symptoms/symptom clusters and cytokines in patients with advanced non-small-cell lung cancer (NSCLC) at pretreatment and at 1 month, 3 months, and 6 months after gefitinib treatment. Methods: Fifty-seven patients with NSCLC were recruited via convenience sampling from a group of thoracic oncology patients in Northern Taiwan. Research measures included the use of the M.D. Anderson Symptom Inventory-Taiwan form and enzyme-linked immunosorbent assays. Statistical analyses included descriptive statistics and generalized estimating equation analysis. Results: Positive relationships were observed between interleukin (IL)-2 and nausea (p
AB - Purpose: Several cytokines involved in the development of sickness behaviors are considered to be related to the development of cancer symptoms. However, the mechanism of cytokines' involvement in symptom relief with gefitinib treatment remains unknown. This study analyzed the relationships between single symptoms/symptom clusters and cytokines in patients with advanced non-small-cell lung cancer (NSCLC) at pretreatment and at 1 month, 3 months, and 6 months after gefitinib treatment. Methods: Fifty-seven patients with NSCLC were recruited via convenience sampling from a group of thoracic oncology patients in Northern Taiwan. Research measures included the use of the M.D. Anderson Symptom Inventory-Taiwan form and enzyme-linked immunosorbent assays. Statistical analyses included descriptive statistics and generalized estimating equation analysis. Results: Positive relationships were observed between interleukin (IL)-2 and nausea (p
KW - Cytokines
KW - Gefitinib therapy
KW - Non-small-cell lung cancer
KW - Symptom cluster
UR - http://www.scopus.com/inward/record.url?scp=84897979138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897979138&partnerID=8YFLogxK
U2 - 10.1016/j.jecm.2014.02.009
DO - 10.1016/j.jecm.2014.02.009
M3 - Article
AN - SCOPUS:84897979138
VL - 6
SP - 50
EP - 56
JO - Journal of Experimental and Clinical Medicine
JF - Journal of Experimental and Clinical Medicine
SN - 1878-3317
IS - 2
ER -